How COVID-19 vaccine options are expanding with another EUA

The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to the SARS-CoV-2 vaccine developed by Moderna Inc. for use in people 18 or older. The vaccine joins Pfizer-BioNTech’s vaccine, which earned FDA authorization last week.

Both vaccines use the messenger RNA technology, consist of two separate doses per patient, and have shown about 95% efficacy in protecting against COVID-19, compared with placebo, in clinical trials involving tens of thousands of participants.

Moderna has said it plans to ship 20 million U.S. doses in December, another 80 million by March 2021, and an additional 100 million by June 2021.

My latest for the AMA. The whole shebang.

The AMA’s top 10 stories of 2020

The COVID-19 pandemic has exacted a toll on physicians battling to save lives that has been unlike any other in living memory. For months, the AMA has advocated fiercely to get doctors the personal protective equipment (PPE) they deserve, and the financial support they need to survive the pandemic’s economic strain.

Physician readers, awakened to the new demands of practicing and serving patients amid the novel coronavirus, have frequently turned to the AMA as a powerful ally for insightful, timely news coverage on top-of-mind issues such as patient questions on mask-wearing and how to reopen practice safely. That coverage includes an outstanding new offering in 2020, the “AMA COVID-19 Update” daily video series.

Here are the AMA’s top 10 stories of the year.

My latest for the AMA. The whole shebang.

Some other recent articles: